Literature DB >> 11825053

Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use.

W Hope1, A Morton, D P Eisen.   

Abstract

Candida is an important nosocomial pathogen. This study was undertaken to provide information on the rate of candidaemia, to define the risks for candidaemia and to describe and account for the epidemiology of candidaemia at our institution between 1992 and 1999. The overall rate was 0.052 per 1000 patient days and 0.27 per 1000 discharges. The major risks for candidaemia were colonization at a non-sterile site (OR 3.85, 95%CI 1.80-9.09), total parenteral nutrition (TPN) in the absence of neutropenia (OR 11.8, 95%CI 4.5-35.4, P<0.001) and neutropenia in the absence of TPN (OR 3.7, 95%CI 1.8-7.7, P<0.001). There was no change in the overall incidence of candidaemia but there was a steady decline in the rate of C. albicans with a corresponding rise in the incidence of non- C. albicans species. C. krusei was highly associated with fluconazole exposure (chi(2)=20.78, P<0.001). There was no evidence of spread of C. krusei using random amplification of polymorphic DNA, suggesting the appearance of this organism was due to the selection pressure exerted by fluconazole. Copyright 2001 The Hospital Infection Society.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11825053     DOI: 10.1053/jhin.2001.1131

Source DB:  PubMed          Journal:  J Hosp Infect        ISSN: 0195-6701            Impact factor:   3.926


  24 in total

1.  Comparison of in vitro susceptibility characteristics of Candida species from cases of invasive candidiasis in solid organ and stem cell transplant recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006.

Authors:  Shawn R Lockhart; Debra Wagner; Naureen Iqbal; Peter G Pappas; David R Andes; Carol A Kauffman; Lisa M Brumble; Susan Hadley; Randall Walker; James I Ito; John W Baddley; Tom Chiller; Benjamin J Park
Journal:  J Clin Microbiol       Date:  2011-05-11       Impact factor: 5.948

2.  Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study.

Authors:  Michael Y Lin; Yehuda Carmeli; Jennifer Zumsteg; Ernesto L Flores; Jocelyn Tolentino; Pranavi Sreeramoju; Stephen G Weber
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

3.  Factors Influencing Non-albicans Candidemia: A Case-Case-Control Study.

Authors:  Diamantis P Kofteridis; Antonis Valachis; Dimitra Dimopoulou; Angeliki M Andrianaki; Athanasia Christidou; Sofia Maraki; Nikolaos A Spernovasilis; George Samonis
Journal:  Mycopathologia       Date:  2017-05-19       Impact factor: 2.574

4.  Caspofungin use in patients with invasive candidiasis caused by common non-albicans Candida species: review of the caspofungin database.

Authors:  Arnaldo L Colombo; Angela L Ngai; Michael Bourque; Susan K Bradshaw; Kim M Strohmaier; Arlene F Taylor; Robert J Lupinacci; Nicholas A Kartsonis
Journal:  Antimicrob Agents Chemother       Date:  2010-03-15       Impact factor: 5.191

5.  Update on Antifungal Drug Resistance.

Authors:  David S Perlin; Erika Shor; Yanan Zhao
Journal:  Curr Clin Microbiol Rep       Date:  2015-06-01

6.  Multilocus microsatellite markers for molecular typing of Candida glabrata: application to analysis of genetic relationships between bloodstream and digestive system isolates.

Authors:  A Enache-Angoulvant; M Bourget; S Brisse; C Stockman-Pannier; L Diancourt; N François; D Rimek; C Fairhead; Daniel Poulain; C Hennequin
Journal:  J Clin Microbiol       Date:  2010-09-15       Impact factor: 5.948

Review 7.  Infection in Burns.

Authors:  William Norbury; David N Herndon; Jessica Tanksley; Marc G Jeschke; Celeste C Finnerty
Journal:  Surg Infect (Larchmt)       Date:  2016-04       Impact factor: 2.150

8.  Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection.

Authors:  S Takakura; N Fujihara; T Saito; T Kudo; Y Iinuma; S Ichiyama
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

9.  Global distribution and outcomes for Candida species causing invasive candidiasis: results from an international randomized double-blind study of caspofungin versus amphotericin B for the treatment of invasive candidiasis.

Authors:  A L Colombo; J Perfect; M DiNubile; K Bartizal; M Motyl; P Hicks; R Lupinacci; C Sable; N Kartsonis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-07-23       Impact factor: 3.267

10.  Candida krusei, a multidrug-resistant opportunistic fungal pathogen: geographic and temporal trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005.

Authors:  M A Pfaller; D J Diekema; D L Gibbs; V A Newell; E Nagy; S Dobiasova; M Rinaldi; R Barton; A Veselov
Journal:  J Clin Microbiol       Date:  2007-12-12       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.